David Brookes

Anatara Lifesciences Ltd | Executive Chairman, Executive Director

Dr Brookes was appointed the Chair of the Audit Committee which he subsequently resigned from on 18 October 2022. Remains a Member of the Audit Committee and is a member of the Remuneration and Nomination Committee. He has extensive experience in the health and biotechnology industries and held Board positions in a number of ASX listed biotechnology companies, including as Chairman of genomics solutions company, RHS Ltd, which was acquired by PerkinElmer Inc (NYSE:PKI) in June 2018.

Companies and Roles

Company	Title	Tenure	Since
ANR Anatara Lifesciences Ltd	Executive Chairman Executive Director	4yrs, 3mth	Jun 2022
TD1 TALI Digital Limited	Executive Chairman Executive Director	6yrs, 3mth	Jun 2020
DLM Dominion Minerals Limited	Non-Executive Director Non-Executive Chairman	7yrs, 6mth	Apr 2019

Holdings

Company	Last Notice	Direct Shares	Indirect Shares	Options	Convertibles
TD1 TALI Digital Limited	29/09/26	290,003	1,870,002	713,333	N/A
ANR Anatara Lifesciences Ltd	11/12/25	1,240,000	8,623,336	2,500,000	N/A
IVG	04/06/25	1,371,250	6,030,000	1,731,120	N/A
ILA	30/04/24	N/A	140,000	40,000	N/A
DLM Dominion Minerals Limited	31/12/23	N/A	4,901,250	500,000	N/A

Transactions

Company	Date	Type	Amount	Price	Value	Notes
TD1 TALI Digital Limited	29/09/26	Buy	1,600,000	$0.050	$80,000	Placement
TD1 TALI Digital Limited	29/09/26	Buy	533,333	$0.088	$46,933	Participation in share purchase plan
ANR Anatara Lifesciences Ltd	11/12/25	Expiry	932,143	$0.012	$11,185	Options expired
ANR Anatara Lifesciences Ltd	26/11/25	Issued	3,333,334	$0.012	$40,000	Placement
TD1 TALI Digital Limited	11/07/25	Issued	5,814,300	$0.001	$5,814	Rights issue

Any feedback about this profile? Contact Us

Build your watchlist

Already have account? Log in